加载中
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
前收盘价
US$1.58
−US$0.10 · -5.95%
盘前
US$1.57
−US$0.01 · -0.63%
10月12日 5:37 ET
盘中时间采用ET。市场数据可能有所延迟。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日内区间
当前US$1.58
52周区间
当前US$1.58
盘中时间采用ET。市场数据可能有所延迟。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日内区间
当前US$1.58
52周区间
当前US$1.58
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5665.1万 USD | 5129.2万 USD | 3929.5万 USD | 2246.9万 USD | 1303.6万 USD |
| 销货成本 | 831.1万 USD | 833.4万 USD | 625.6万 USD | 499.9万 USD | 364万 USD |
| 毛利 | 4834万 USD | 4295.8万 USD | 3303.9万 USD | 1747万 USD | 939.6万 USD |
| 研究与开发 | 1113.2万 USD | 1113.1万 USD | 1163.3万 USD | 995.2万 USD | 750.1万 USD |
| 销售、一般及管理费用 | 8847.3万 USD | 9131.7万 USD | 6450.9万 USD | 5004.5万 USD | 2786.3万 USD |
| 营业费用 | 9960.5万 USD | 1.02亿 USD | 7614.2万 USD | 5999.7万 USD | 3536.4万 USD |
| 利息支出 | 582.7万 USD | 439.7万 USD | 179.9万 USD | 16.5万 USD | 221.9万 USD |
| 折旧和摊销 | 75.6万 USD | 61.9万 USD | 52.2万 USD | 41.2万 USD | 16.8万 USD |
| 营业利润 | −5126.5万 USD | −5949万 USD | −4310.3万 USD | −4252.7万 USD | −2596.8万 USD |
| 净利润 | −5330.6万 USD | −5996.5万 USD | −4119.9万 USD | −4142.8万 USD | −4307.8万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.30
上涨空间 172.15%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI202.5万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM63.79万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF60.54万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO26.11万0.00%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO26.07万0.00%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC8.21万0.01%13.17亿 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6万0.05%1.17亿 USD0.73%US$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG5.16万0.00%17亿 USD0.06%US$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
